Through the expanding next-generation sequencing (NGS) oncology portfolio, Genestrings bring forth the revolution in cancer genomics. Our NGS technologies in with targeted cancer panel, promises to deliver high-quality, reproducible results to speed the discovery and analysis of cancer-related variants—and potentially transform the cancer care cycle across different cancer types such as lung, breast, head and neck, pancreatic, colorectal, cervical, childhood, ovarian, kidney, lymphomas and leukemia.
Cancer Sequencing Methods
- GenemineComprehensive Panel-Content based on latest advances in clinical oncology
Research.Detects relevant SNVs, CNVs, gene fusions, and indelsfrom 161 unique cancer driver genes. Sample Type-FFPE, Biopsy, Fresh Tissue
- GenemineFocus Panel-Analyses around 1000 biomarkers across 52 genes using next-generation sequencing (NGS) relevant to solid tumors.This assay allows concurrent analysis of DNA and RNA tosimultaneously detect multiple types of variants, includinghotspots, single nucleotide variants (SNVs), indels, copy numbervariants (CNVs) and gene fusions.
- GenemineBRCA Panel-Inherited mutations in BRCA1/2 are associated with an increased risk of certain cancers, including breast and ovarian cancer. Somatic mutations in BRCA1/2 are common in several cancer type.The recommended input is DNA which may be extracted from blood, cell lines, or formalin-fixed, paraffin-embedded (FFPE) samples.Single-nucleotide variants (SNVs), multi-nucleotide variants (MNVs), short insertions or deletions (indels), and whole-exon, multiple-exon, or entire-gene aberrations are detected with high sensitivity and specificity.
GenemineChildhood Cancer Panel-Childhood Cancer Panel is a unique,NGS-based tool designed for comprehensive genomic profiling of cancers affecting children and young adults.
- Genemine Exome Panel-Exome sequencing is a fast and affordable alternative to using whole genome sequencing and allows identification of somatic and germline genetic variants within coding regions of genes.This panel enables high on-target sequencing reads with uniform coverage from both archived FFPE samples and fresh-frozen tissues. Ideal for exome sequencing of tumor samples, normal/tumor pairs, and primary/metastatic tumor pairs, this easy-to-use sequencing kit enables consistent and reliable results across multiple tissue sources.
Liquid Biopsy Assay-cfDNA(Blood)
cfDNA Assays are tumor type–specific, multi-biomarkernext-generation sequencing (NGS) assays that enable detection of somatic mutations, down to a level of 0.1% with>98% specificity, in genes found in plasma samples. Lung, Breast and Colon Panels taget specific cancers whereas Pan-Cancer panel isasolution to detect multiple targets in tumor-derived DNA and RNA isolated from the plasma fraction of whole blood.
The panel is comprised of 40 key DNA genes and a broad fusion panel of 29 driver genes to cover the most relevant targets in major myeloid disorders: acute myeloid leukemia (AML), myeloid dysplastic syndrome (MDS), myeloproliferative neoplasms (MPN), chronic myeloid leukemia (CML), chronic myelomonocytic leukemia (CMML), and juvenile myelomonocytic leukemia (JMML).The assay is designed to provide sensitive and comprehensive sample amplification of relevant DNA mutations and fusion transcripts associated with myeloid disorders in a single NGS run.